Universal Aspirin in High-Risk Pregnancies? - Summary - MDSpire

Universal Aspirin in High-Risk Pregnancies?

Direct dispensation at first prenatal visit delays onset, reduces rates in high-risk population without increasing hemorrhage.

  • By

  • Kerri Miller

  • February 11, 2026

  • 3 min

Share

Objective:

To evaluate the impact of universal aspirin dispensation on the rate of preeclampsia with severe features in high-risk pregnancies.

Key Findings:
  • Preeclampsia with severe features (SPE) rate decreased from 7% to 5%.
  • Time to SPE diagnosis was significantly longer in the aspirin group.
  • Gestational hypertension rates declined from 21% to 19%.
  • Preterm delivery before 37 weeks reduced from 10% to 9%.
  • Postpartum hemorrhage rates decreased from 9.5% to 8.9%.
Interpretation:

Aspirin administration in high-risk pregnancies appears to delay or prevent the onset of preeclampsia with severe features without significant harm.

Limitations:
  • Observational study design limits causation inference.
  • Results may not generalize to other populations with different risk profiles.
Conclusion:

Directly-dispensed aspirin in high-risk pregnancies showed promising results in reducing severe preeclampsia rates without adverse effects.

Original Source(s)

Universal Aspirin in High-Risk Pregnancies?

  • by Kerri Miller

  • February 11, 2026

Related Content

Robotic single-port (SP) vaginal hysterectomy: the first cases in Europe and surgical steps

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Prepregnancy Lipids Predict HDP Risk

A large Swedish cohort found cardiometabolic biomarkers measured up to decades before pregnancy were associated with hypertensive disorders — with risk apparent even below standard diagnostic thresholds.